← Oncology Approval Tracker

FDA DECISION ·

Nubeqa + docetaxel

darolutamide plus docetaxel · Bayer

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic hormone-sensitive prostate cancer receiving darolutamide together with docetaxel.

LAMPGEN ANALYSIS

Why it matters

The 2022 decision is for the docetaxel combination in the hormone-sensitive setting.

What research teams should watch

Confirm metastatic and hormone-sensitive status and align androgen deprivation, docetaxel and oral therapy workflows.

PRIMARY RECORDS

Sources